TD Private Client Wealth LLC Has $1.49 Million Stock Holdings in West Pharmaceutical Services, Inc. (NYSE:WST)

TD Private Client Wealth LLC raised its holdings in West Pharmaceutical Services, Inc. (NYSE:WST) by 7.2% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 4,542 shares of the medical instruments supplier’s stock after acquiring an additional 305 shares during the period. TD Private Client Wealth LLC’s holdings in West Pharmaceutical Services were worth $1,488,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently added to or reduced their stakes in the company. Whipplewood Advisors LLC acquired a new stake in shares of West Pharmaceutical Services in the fourth quarter worth $25,000. Retirement Wealth Solutions LLC acquired a new stake in West Pharmaceutical Services in the 4th quarter worth $34,000. Centricity Wealth Management LLC acquired a new position in shares of West Pharmaceutical Services during the fourth quarter valued at about $35,000. Cornerstone Planning Group LLC lifted its stake in shares of West Pharmaceutical Services by 57.1% in the fourth quarter. Cornerstone Planning Group LLC now owns 110 shares of the medical instruments supplier’s stock valued at $38,000 after buying an additional 40 shares during the period. Finally, Brooklyn Investment Group bought a new stake in shares of West Pharmaceutical Services in the third quarter valued at about $41,000. 93.90% of the stock is owned by institutional investors.

West Pharmaceutical Services Stock Performance

West Pharmaceutical Services stock opened at $229.03 on Friday. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.79 and a quick ratio of 2.23. The stock has a fifty day moving average price of $274.78 and a two-hundred day moving average price of $300.47. West Pharmaceutical Services, Inc. has a 52-week low of $197.01 and a 52-week high of $397.72. The firm has a market capitalization of $16.56 billion, a P/E ratio of 34.23, a P/E/G ratio of 6.74 and a beta of 1.09.

West Pharmaceutical Services (NYSE:WST) last released its quarterly earnings data on Thursday, February 13th. The medical instruments supplier reported $1.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.75 by $0.07. The firm had revenue of $748.80 million during the quarter, compared to analyst estimates of $739.59 million. West Pharmaceutical Services had a return on equity of 18.60% and a net margin of 17.03%. As a group, analysts anticipate that West Pharmaceutical Services, Inc. will post 6.62 EPS for the current fiscal year.

West Pharmaceutical Services Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, May 7th. Stockholders of record on Wednesday, April 30th will be issued a dividend of $0.21 per share. This represents a $0.84 annualized dividend and a dividend yield of 0.37%. The ex-dividend date is Wednesday, April 30th. West Pharmaceutical Services’s payout ratio is presently 12.56%.

Analysts Set New Price Targets

WST has been the subject of several recent research reports. KeyCorp cut their price target on West Pharmaceutical Services from $470.00 to $325.00 and set an “overweight” rating for the company in a report on Friday, February 14th. StockNews.com lowered West Pharmaceutical Services from a “buy” rating to a “hold” rating in a research note on Thursday, February 27th. Evercore ISI initiated coverage on West Pharmaceutical Services in a research note on Tuesday, March 18th. They issued an “outperform” rating and a $275.00 target price for the company. Bank of America upped their target price on West Pharmaceutical Services from $350.00 to $355.00 and gave the company a “buy” rating in a research note on Friday, December 13th. Finally, Wolfe Research initiated coverage on West Pharmaceutical Services in a research note on Friday, December 13th. They issued a “peer perform” rating for the company. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, West Pharmaceutical Services presently has a consensus rating of “Moderate Buy” and a consensus price target of $332.50.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.